- Home
- TECH vs WYNN Comparison
TECH vs WYNN Comparison
Compare TECH & WYNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECH
- WYNN
- Stock Information
- Founded
- TECH 1976
- WYNN 2002
- Country
- TECH United States
- WYNN United States
- Employees
- TECH N/A
- WYNN N/A
- Industry
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- WYNN Hotels/Resorts
- Sector
- TECH Health Care
- WYNN Consumer Discretionary
- Exchange
- TECH Nasdaq
- WYNN Nasdaq
- Market Cap
- TECH 11.3B
- WYNN 10.4B
- IPO Year
- TECH 1989
- WYNN 2002
- Fundamental
- Price
- TECH $73.17
- WYNN $88.95
- Analyst Decision
- TECH Buy
- WYNN Strong Buy
- Analyst Count
- TECH 8
- WYNN 13
- Target Price
- TECH $82.00
- WYNN $117.15
- AVG Volume (30 Days)
- TECH 795.5K
- WYNN 2.0M
- Earning Date
- TECH 01-30-2025
- WYNN 02-05-2025
- Dividend Yield
- TECH 0.44%
- WYNN 1.12%
- EPS Growth
- TECH N/A
- WYNN 2755.61
- EPS
- TECH 0.95
- WYNN 8.43
- Revenue
- TECH $1,171,583,000.00
- WYNN $7,129,624,000.00
- Revenue This Year
- TECH $7.67
- WYNN $10.79
- Revenue Next Year
- TECH $9.38
- WYNN $2.11
- P/E Ratio
- TECH $77.07
- WYNN $10.56
- Revenue Growth
- TECH 2.41
- WYNN 25.16
- 52 Week Low
- TECH $61.16
- WYNN $71.63
- 52 Week High
- TECH $85.57
- WYNN $110.38
- Technical
- Relative Strength Index (RSI)
- TECH 46.90
- WYNN 42.07
- Support Level
- TECH $69.48
- WYNN $87.36
- Resistance Level
- TECH $77.62
- WYNN $92.95
- Average True Range (ATR)
- TECH 2.45
- WYNN 2.71
- MACD
- TECH -0.45
- WYNN -0.67
- Stochastic Oscillator
- TECH 41.28
- WYNN 12.97
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
About WYNN Wynn Resorts Limited Common stock
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming attractions in Macao over the next few years. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and the US, respectively.